FR05C0027I2 - - Google Patents

Info

Publication number
FR05C0027I2
FR05C0027I2 FR05C0027C FR05C0027C FR05C0027I2 FR 05C0027 I2 FR05C0027 I2 FR 05C0027I2 FR 05C0027 C FR05C0027 C FR 05C0027C FR 05C0027 C FR05C0027 C FR 05C0027C FR 05C0027 I2 FR05C0027 I2 FR 05C0027I2
Authority
FR
France
Prior art keywords
conopeptide
omega
medicament
manufacture
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR05C0027C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/496,847 external-priority patent/US5795864A/en
Priority claimed from US08/613,400 external-priority patent/US6054429A/en
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of FR05C0027I1 publication Critical patent/FR05C0027I1/fr
Application granted granted Critical
Publication of FR05C0027I2 publication Critical patent/FR05C0027I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Control Of El Displays (AREA)
  • Saccharide Compounds (AREA)
FR05C0027C 1995-06-27 2005-06-23 Active FR05C0027I2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/496,847 US5795864A (en) 1995-06-27 1995-06-27 Stable omega conopetide formulations
US08/613,400 US6054429A (en) 1996-03-08 1996-03-08 Epidural method of producing analgesia
PCT/US1996/011041 WO1997001351A1 (en) 1995-06-27 1996-06-26 Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders

Publications (2)

Publication Number Publication Date
FR05C0027I1 FR05C0027I1 (es) 2005-08-12
FR05C0027I2 true FR05C0027I2 (es) 2006-12-29

Family

ID=27052304

Family Applications (1)

Application Number Title Priority Date Filing Date
FR05C0027C Active FR05C0027I2 (es) 1995-06-27 2005-06-23

Country Status (14)

Country Link
EP (2) EP0835126B1 (es)
JP (1) JP2838073B2 (es)
AT (2) ATE359086T1 (es)
AU (1) AU695166B2 (es)
CA (1) CA2224795C (es)
DE (3) DE69627153T2 (es)
DK (2) DK0835126T3 (es)
ES (2) ES2283671T3 (es)
FR (1) FR05C0027I2 (es)
HK (1) HK1058146A1 (es)
LU (1) LU91181I2 (es)
NL (1) NL300201I2 (es)
PT (2) PT835126E (es)
WO (1) WO1997001351A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5931809A (en) * 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
EP1054896A1 (en) * 1998-02-20 2000-11-29 Zeneca Limited ANALGESIC PEPTIDES FROM VENOM OF $i(GRAMMOSTOLA SPATULATA) AND USE THEREOF
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
EP2412719A1 (en) 2002-12-02 2012-02-01 Xenome Ltd Chi-conotoxin peptides
ES2383358T3 (es) 2002-12-02 2012-06-20 Xenome Ltd Péptidos de chi-conotoxina que tienen un ácido piroglutámico N-terminal
SG192300A1 (en) 2003-01-28 2013-08-30 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1689401A1 (en) 2003-10-02 2006-08-16 Elan Pharmaceuticals, Inc. Method for reducing pain
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
JP2010509209A (ja) * 2006-11-04 2010-03-25 エニジェン カンパニー リミテッド 新規なω−コノトキシン
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
EP2300044A4 (en) * 2008-05-06 2012-04-18 Relevare Aust Pty Ltd METHOD AND COMPOSITIONS FOR TREATING PAIN WITH OMEGA CONOTOXINES
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010065751A2 (en) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2010078449A2 (en) 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN104902930A (zh) 2012-08-21 2015-09-09 阿德利克斯公司 在治疗与液体潴留或盐分过载相关的疾病和胃肠道疾病中用于抑制nhe-介导的反向转运的化合物和方法
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HUE044550T2 (hu) 2013-04-12 2019-11-28 Ardelyx Inc NHE-3 megkötõ vegyületek és foszfát transzport gátlási módszerek
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
CN110267944B (zh) 2017-01-09 2024-03-08 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Ｎｈｅ媒介性アンチポートの阻害薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
WO1993010145A1 (en) * 1991-11-12 1993-05-27 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
AU689438B2 (en) * 1991-12-30 1998-04-02 Azur Pharma International Limited Methods of producing analgesia and enhancing opiate analgesia
JPH06247879A (ja) * 1993-02-17 1994-09-06 Bristol Myers Squibb Co デオキシチミジンヌクレオシドを含有する注射用製剤の安定化方法およびその方法によって得られる安定化注射用製剤

Also Published As

Publication number Publication date
PT1336409E (pt) 2007-06-29
DE69637021D1 (de) 2007-05-24
EP0835126B1 (en) 2003-04-02
ES2194998T3 (es) 2003-12-01
ES2283671T3 (es) 2007-11-01
DK1336409T3 (da) 2007-08-13
DE69627153D1 (de) 2003-05-08
HK1058146A1 (en) 2004-05-07
DE69627153T2 (de) 2003-12-04
EP1336409B1 (en) 2007-04-11
LU91181I2 (fr) 2005-09-06
ATE235914T1 (de) 2003-04-15
AU6400296A (en) 1997-01-30
CA2224795A1 (en) 1997-01-16
JP2838073B2 (ja) 1998-12-16
CA2224795C (en) 2001-04-03
DE122005000043I2 (de) 2006-08-03
EP1336409A1 (en) 2003-08-20
NL300201I2 (nl) 2006-02-01
JPH09104634A (ja) 1997-04-22
NL300201I1 (nl) 2005-09-01
DK0835126T3 (da) 2003-07-14
DE122005000043I1 (de) 2006-06-29
DE69637021T2 (de) 2008-01-10
ATE359086T1 (de) 2007-05-15
PT835126E (pt) 2003-07-31
FR05C0027I1 (es) 2005-08-12
WO1997001351A1 (en) 1997-01-16
AU695166B2 (en) 1998-08-06
EP0835126A1 (en) 1998-04-15

Similar Documents

Publication Publication Date Title
FR05C0027I2 (es)
HK1008180A1 (en) Use of vitamin d 2 or vitamin d 4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
IL123601A0 (en) Use of epinastine for the treatment of pain
IL121170A0 (en) Compositions for the treatment of dermatological disorders
GB2298440B (en) Well treatment
AU7545594A (en) Implantable device for the treatment of aedemas
ZA9610139B (en) Treatment of the cns effects of hiv
AU6328696A (en) Treatment of hemoglobinopathies
EP0668527A3 (en) Manufacture of a frictionless liquid crystal display device.
AU3105095A (en) Device for ensuring that medication is taken at the correct time
AU1578295A (en) Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
GB9303157D0 (en) Treatment of a group of related disorders
EP0765661A3 (en) Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
AP9200355A0 (en) "Therapeutic agent"
HU9502623D0 (en) Use of substituted alkyl-nitrates for the treatment of pathologically increased intraocular pressure
GB9419048D0 (en) Treatment of muscular disorders
AU7726796A (en) Use of 3-oxa-d-prostaglandins for the manufacture of a medicament for the treatment of glaucoma
ZA947912B (en) Treatment of medical disorders associated with free radical formation
SI0778025T1 (en) Use of 8,9-dehydroestrone for the manufacture of a medicament for the treatment of diseases caused by free radicals
AU5419894A (en) Dental treatment aid
EP0622079A3 (en) Gelatinase A for the treatment of Alzheimer's disease.
GB9505681D0 (en) "Treatment"
AU5397994A (en) Treatment of skin disorders